AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma - LARVOL DELTA

Successful Treatment of Refractory Pyoderma Gangrenosum with Vunakizumab: A Case Report (EADV 2026) - "Treatment with an individualized regimen of Vunakizumab plus low-dose glucocorticoids and low-dose cyclosporine resulted in pain relief and gradual healing of the cutaneous ulcers. No severe adverse events, including serious infections or hepatorenal injury, occurred during the entire treatment course, demonstrating a favorable safety profile. Conclusion The combination of Vunakizumab with low-dose glucocorticoids and low-dose cyclosporine reduces tissue damage and ulcer formation, providing a new therapeutic direction and insight for the clinical management of RPG."

Case report • Clinical • Acute Kidney Injury • Cardiovascular • Dermatopathology • Diabetes • Hematological Disorders • Hepatology • Hypertension • Immunology • Infectious Disease • Pyoderma Gangrenosum • Renal Disease • Thrombocytopenia • Vasculitis

Successful Treatment of Generalized Pustular Psoriasis with Vunakizumab: A Case Series (EADV 2026) - "Case 3:The patient had received two treatments with ustekinumab (an IL-12/23 inhibitor). It was well tolerated without severe adverse events, even in patients with significant comorbidities. Vunakizumab represents an effective and safe targeted option for GPP."

Clinical • Cardiovascular • Chronic Kidney Disease • Chronic Obstructive Pulmonary Disease • Congestive Heart Failure • Dermatology • Gastrointestinal Disorder • Heart Failure • Immunology • Infectious Disease • Inflammation • Psoriasis • Pulmonary Disease • Pustular Psoriasis • Renal Disease • Respiratory Diseases • IL12A • IL17A • IL22 • TNFA

Efficacy and safety of vunakizumab in the treatment of non-common subtypes of psoriasis: A case report of three Patients (EADV 2026) - "These patients frequently exhibit inadequate responses, high relapse rates, or poor tolerability to traditional systemic therapies (e.g., cyclosporine, acitretin), representing a significant unmet clinical need. DLQI scores decreased significantly: in the EP patient from 13 to 1, in the GPP patient from 11 to 1, and in the PPP patient from 11 to 2 at Week 12. Keywords : erythrodermic psoriasis; generalized pustular psoriasis; palmoplantar pustulosis; vunakizumab; interleukin-17A"

Case report • Clinical • Dermatology • Immunology • Inflammation • Plaque Psoriasis • Psoriasis • Pustular Psoriasis • IL17A

Effectiveness and Safety of Vunakizumab in Patients with Moderate-to-Severe Plaque Psoriasis: A Preliminary Analysis of a Real-World Prospective Study (EADV 2026) - P | "J Am Acad Dermatol. 2025; 92(1):92-99."

Clinical • Real-world • Real-world evidence • Atopic Dermatitis • Cardiovascular • Dermatology • Immunology • Infectious Disease • Plaque Psoriasis • Pruritus • Psoriasis • Respiratory Diseases

Successful Treatment of a Patient with Severe Plaque Psoriasis Complicated by Pustular Psoriasis Using Vunakizumab (EADV 2026) - "Accumulating clinical evidence has demonstrated the efficacy of interleukin‑17 (IL‑17) inhibitors, such as secukinumab and ixekizumab, in the management of PP. A 42-year-old male patient with a 10-year history of psoriasis presented with recurrent trunk and extremity rashes 5 months prior, without obvious precipitating factors. Oral administration of viaminate capsules and thymosin enteric-coated tablets failed to control the disease, instead exacerbating it and leading to generalized skin lesions. The patient developed generalized cutaneous erythema, swelling and pain in both lower extremities, and white pustules on the back; he was diagnosed with plaque psoriasis complicated by pustular psoriasis, with 90% BSA involvement, a PASI score of 64.8, and a DLQI score of 19."

Clinical • Dermatology • Immunology • Plaque Psoriasis • Pruritus • Psoriasis • Pustular Psoriasis • IL17A

Successful Treatment of A 75-year-old Male with Severe Plaque Psoriasis Using Vunakizumab (antiIL-17)- A Case Report (EADV 2026) - P3 | "Previous treatments included Acitretin and phototherapy, both with suboptimal efficacy. Subsequently, the patient received Secukinumab therapy...No adverse events were observed during the treatment period. Further studies are warranted to provide additional evidence for the use of Vunakizumab in the treatment of psoriasis in the elderly population."

Case report • Clinical • Dermatology • Immunology • Inflammation • Plaque Psoriasis • Pruritus • Psoriasis • IL17A

Successful Treatment of Severe Generalized Pustular Psoriasis With Concomitant Infection Using Vunakizumab in an 87-Year-Old Patient: A Case Report (EADV 2026) - "The patient received anti-infective therapy, including Tanreqing injection (20 mL, intravenously once daily for 11 days), levofloxacin (100 mL, intravenously once daily for 10 days), and oral carbocisteine (0.5 g twice daily for 10 days). Conclusion This case demonstrates that vunakizumab achieved rapid disease control and was well tolerated in an ultra-elderly patient with GPP complicated by infection. It highlights the potential feasibility of initiating IL-17A inhibition in carefully selected elderly patients with GPP following adequate resolution of concomitant infection."

Case report • Clinical • Bronchiectasis • Dermatology • Dermatopathology • Geriatric Disorders • Hepatitis B • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Plaque Psoriasis • Pneumonia • Pruritus • Psoriasis • Pulmonary Disease • Pustular Psoriasis • Respiratory Diseases • Tuberculosis • IL17A

Rapid Response to Vunakizumab in an Elderly Patient with Generalized Pustular Psoriasis Masquerading as Acute Generalized Exanthematous Pustulosis: A Case Report (EADV 2026) - "Intravenous methylprednisolone 60 mg/day was initiated, along with supportive anti-infective therapy. Conclusion Vunakizumab, a monoclonal antibody targeting IL-17A, demonstrated rapid clinical efficacy and good tolerability in an elderly patient with GPP prior to definitive diagnosis, enabling prompt tapering and discontinuation of systemic corticosteroids and minimizing steroid-related adverse effects. This report highlights the diagnostic challenges posed by the clinical overlap between GPP and AGEP, and to demonstrate the effectiveness of Vunakizumab in such complex clinical settings, reinforcing the importance of accurate diagnosis and timely intervention."

Case report • Clinical • Dermatology • Immunology • Inflammation • Plaque Psoriasis • Psoriasis • Pustular Psoriasis • IL17A

Real-world efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis: a prospective cohort study analysing BMI as a predictor of response (EADV 2026) - "Weight status is a critical factor when counselling patients on treatment expectations. Future studies should explore whether weight-adjusted dosing or weight management may help improve therapeutic efficacy."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Acne Vulgaris • Alopecia • Dermatology • Immunology • Musculoskeletal Pain • Obesity • Plaque Psoriasis • Psoriasis • IL17A

Vunakizumab Achieve Complete Remission of Severe Plaque Psoriasis in a 25-Year-Old Male with HIV Infection: A Case Report (EADV 2026) - "By W8, complete skin clearance was achieved with only residual pigmentation, and no active lesions were present. Conclusion Vunakizumab led to PASI 100 in a patient with severe plaque psoriasis and HIV co-infection within eight weeks, while maintaining HIV stability and a favorable safety profile.As HIV-positive patients are often excluded from trials, real-world evidence like this case backs vunakizumab as a feasible, effective choice for this refractory group."

Case report • Clinical • Dermatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Plaque Psoriasis • Psoriasis • CD4 • IL17A

Real-world efficacy and safety of vunakizumab in scalp psoriasis: a prospective cohort study (EADV 2026) - "Conclusions Vunakizumab demonstrated rapid, high-rate scalp clearance with a favourable short-term safety profile in real-world practice. The complete resolution of quality-of-life impairment across the cohort supports vunakizumab as an effective and well-tolerated treatment option for scalp psoriasis."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Acne Vulgaris • Alopecia • Dermatology • Immunology • Musculoskeletal Pain • Plaque Psoriasis • Psoriasis • IL17A

Vunakizumab in the Treatment of Severe Erythrodermic Psoriasis with Multiple Organ Dysfunction: A Case Report (EADV 2026) - "No serious adverse events were reported. Conclusion This case indicates that vunakizumab exhibits rapid efficacy and a favorable safety profile in the treatment of severe erythrodermic psoriasis accompanied by multiple organ dysfunctions, thereby offering a novel therapeutic option for critically ill patients with limited conventional treatment alternatives."

Case report • Clinical • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Dermatology • Diabetes • Heart Failure • Immunology • Inflammation • Metabolic Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Nephrology • Orthopedics • Psoriasis • Renal Disease • Septic Shock • IL17A

Successful treatment of moderate-to-severe hidradenitis suppurativa with Anti-IL-17A Agent Vunakizumab (EADV 2026) - "Our findings suggest that vunakizumab may be a rapid, effective, and well-tolerated therapeutic option for moderate-to-severe HS. As a single case report, these findings require validation in larger, long-term prospective studies."

Candidiasis • Dermatology • Dermatopathology • Hidradenitis Suppurativa • Immunology • Infectious Disease • Inflammation • Respiratory Diseases • IL17A

CARD14 and HLA-Cw6 SNPs as Predictors of Response to IL-17 versus IL-23 Blockade: A Retrospective Real-World Study (EADV 2026) - "Each subgroup was further divided by initial biologic class: IL-17 inhibitors (secukinumab, ixekizumab, vunakizumab) or IL-23 inhibitors (guselkumab, ustekinumab). The integration of HLA-Cw6 and CARD14 testing into clinical decision-making, especially in patients with early-onset disease or relevant clinical histories, has the potential to guide more effective first-line biologic use, reduce empirical treatment approaches, and improve long-term clinical outcomes. Large-sample, prospective, randomized studies are warranted to validate the proposed treatment algorithm and to evaluate the cost-effectiveness of incorporating pretreatment genetic screening into the management pathway for moderate-to-severe psoriasis."

Real-world • Real-world evidence • Retrospective data • Atopic Dermatitis • Immunology • Inflammation • Plaque Psoriasis • Psoriasis • IL17A • IL23A

Follicular Psoriasis Successfully Treated with Vunakizumab: A Case Report (EADV 2026) - "The patient used to be misdiagnosed as eczema or allergic purpura led to ineffective treatments including oral compound glycyrrhizin, levocetirizine, dipyridamole, and topical fluticasone propionate. Initial therapy with oral acitretin (25 mg/day) and topical calcipotriol was discontinued due to intolerable xerostomia...The pathogenesis of FP is still unclear, some researchers suggested that hair follicle immune cells or keratin 17(K17) may be involved the pathogenesis. While further studies are needed, we speculate that in this case, the treatment with vunakizumab precisely blocked the upstream driving signal of this loop (IL-17A), achieving significant results."

Case report • Clinical • Atopic Dermatitis • Dental Disorders • Dermatitis • Dermatology • Dermatopathology • Immunology • Lichen Planus • Pruritus • Psoriasis • Seborrheic Dermatitis • Xerostomia • IL17A • KRT17

Short-Term Efficacy Observation and Medication Analysis of Vunakizumab in the Treatment of Moderate-to-Severe Plaque Psoriasis (EADV 2026) - "As a single-center, retrospective nature with a small sample size and short follow-up period, this study lacks long-term efficacy data. Larger prospective studies are warranted to further validate the real-world efficacy of vunakizumab."

Clinical • Dermatology • Immunology • Plaque Psoriasis • Psoriasis

The impact of immunogenicity on the efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: a post hoc analysis of a phase 3 trial (EADV 2026) - P3 | "Conclusions In patients with moderate-to-severe chronic plaque psoriasis, ADA development with vunakizumab was infrequent. ADA or NAb positivity did not appear to reduce the efficacy or raise safety concerns of vunakizumab, with results consistent with those in the overall population."

Clinical • P3 data • Retrospective data • Dermatology • Immunology • Infectious Disease • Plaque Psoriasis • Psoriasis • IL17A

Efficacy and Safety of Vunakizumab in the Treatment of Moderate to Severe Hidradenitis Suppurativa: A Report of two Cases. (EADV 2026) - "Both patients achieved a HiSCR ≥50%, with no new abscesses or sinus tracts observed. Treatment outcomes in these two patients indicate that vunakizumab yields favorable efficacy in moderate‑to‑severe HS, and might be a valuable option, especially in patients with intense pain and comorbid psoriasis."

Clinical • Cardiovascular • Dermatology • Diabetes • Dyslipidemia • Hepatitis B • Hepatology • Hidradenitis Suppurativa • Human Immunodeficiency Virus • Hypertension • Immunology • Infectious Disease • Inflammation • Metabolic Disorders • Obesity • Psoriasis • IL17A

Efficacy and Safety of Vunakizumab in the Treatment of Moderate-to-Severe Plaque Psoriasis in Patients with High Body Weight (EADV 2026) - "No adverse events were observed. These preliminary findings suggest favorable efficacy and safety of vunakizumab in patients with high body weight, though validation in larger studies is warranted."

Clinical • Dermatology • Immunology • Plaque Psoriasis • Psoriasis

Vunakizumab-induced severe ulcerative colitis during treatment of psoriatic arthritis: a case report and literature review. (PubMed, Front Immunol) - "Vunakizumab was immediately discontinued; intravenous methylprednisolone 60 mg/day was administered to induce remission. The early treatment period (within the first 3 months) represents a high-risk window. Upon diagnosis, immediate drug withdrawal, corticosteroid-induced remission, and prioritized conversion to an IL-23 inhibitor (such as guselkumab) may be considered as a potential option to achieve dual control of intestinal, skin, and joint disease."

Journal • Review • Dermatology • Gastroenterology • Gastrointestinal Disorder • Hepatology • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Liver Failure • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Ulcerative Colitis • IL23A

Vunakizumab Treatment for Pediatric Generalized Pustular Psoriasis: Two Case Reports. (PubMed, J Dermatol) - No abstract available

Journal • Dermatology • Immunology • Pediatrics • Psoriasis • Pustular Psoriasis

Successful treatment of hidradenitis suppurativa with vunakizumab: a case report and literature review. (PubMed, Front Immunol) - "After 8 weeks of treatment with vunakizumab, which offered a pharmacoeconomic advantage during the transition period before its inclusion in China's national insurance system, the patient showed marked improvement, with complete resolution of nodules, abscesses, and tunnels and no recurrence or significant adverse events during 10 months of follow-up. This case highlights the potential of vunakizumab in the treatment of HS and supports the pathogenic role of IL-17 in the disease."

Journal • Review • Dermatology • Hidradenitis Suppurativa • Immunology • Infectious Disease • Inflammation • Pain • IL17A

A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis (clinicaltrials.gov) - P3 | N=208 | Active, not recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting ➔ Active, not recruiting | Trial completion date: Jun 2026 ➔ Jan 2027

Enrollment closed • Trial completion date • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis with a high drug interruption rate during the COVID-19 pandemic: a post hoc analysis from a single center of a phase III trial. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - P3 | "Despite the high drug interruption rate in Huashan Hospital during COVID-19 pandemic, vunakizumab shows acceptable efficacy and safety for treating patients with moderate-to-severe plaque psoriasis. However, the long-term efficacy of vunakizumab appears attenuated in this single-center cohort compared with the overall phase III trial population."

Journal • P3 data • Retrospective data • Dermatology • Immunology • Infectious Disease • Novel Coronavirus Disease • Psoriasis • Respiratory Diseases

A prospective, single-center, randomized study to evaluate the efficacy and safety of changing the dosing schedule for Vunakizumab Injection in the treatment of moderate to severe plaque psoriasis in adults (ChiCTR) - P4 | N=60 | Not yet recruiting | Sponsor: Huashan Hospital, Fudan University; Huashan Hospital, Fudan University

New P4 trial • Dermatology • Immunology • Psoriasis